Ackman noted that Valeant is not considering selling any "core" assets, despite interest from buyers.
The drugmaker on Friday filed its long-delayed annual report, helping it prevent a default on its $30 billion in debt. It pointed out misstatements that would cut some of its previously reported sales.
During a Senate hearing last week on Valeant's drug pricing, Ackman said his first priority was to make sure the company did not go bankrupt.
Many politicians have recently looked to take more action on reining in increases in the price of drugs that aren't widely available. Ackman noted that price cuts at Valeant are "absolutely" on the table.
— Reuters contributed to this report.